文献速递慢性肾脏病

非奈利酮与恩格列净联合治疗慢性肾脏病合并2型糖尿病以尿白蛋白肌酐比值为终点的CONFIDENCE研究设计

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

CONFIDENCE(NCT05254002)是一项随机、对照、双盲、双模拟、国际、多中心、三臂、平行组、为期7.5至8.5个月的2期研究,纳入807例2型糖尿病合并2-3期慢性肾脏病且尿白蛋白肌酐比值≥300至<5000 mg/g的成人。主要目的是证明非奈利酮联合恩格列净治疗6个月在降低白蛋白尿方面优于任一单药治疗。

要点

  • CONFIDENCE研究评估非奈利酮联合恩格列净对比各自单药治疗对尿白蛋白肌酐比值的影响。
  • 研究纳入807例2型糖尿病合并2-3期慢性肾脏病且尿白蛋白肌酐比值≥300至<5000 mg/g的成人。
  • 主要终点为三组间尿白蛋白肌酐比值相对基线的变化。

核心结论

  • CONFIDENCE研究正在评估非奈利酮与SGLT2抑制剂联合用于慢性肾脏病合并2型糖尿病成人的安全性、耐受性和疗效。
  • 若显示出相加效应,早期高效地采用非奈利酮与SGLT2抑制剂联合治疗可能延缓疾病进展并为慢性肾脏病合并2型糖尿病患者带来长期获益。

研究设计与样本

  • CONFIDENCE(NCT05254002)是一项随机、对照、双盲、双模拟、国际、多中心、三臂、平行组、为期7.5至8.5个月的2期研究。
  • 研究纳入807例2型糖尿病合并2-3期慢性肾脏病且尿白蛋白肌酐比值≥300至<5000 mg/g的成人。
  • 干预措施为每日一次非奈利酮10 mg或20 mg(目标剂量)联合恩格列净10 mg,或恩格列净10 mg单药,或非奈利酮10 mg或20 mg(目标剂量)单药。

主要发现

  • 主要结局为三组间尿白蛋白肌酐比值相对基线的变化。
  • 次要结局将进一步表征疗效和安全性,包括估算肾小球滤过率的变化和低钾血症事件。

关键数值与推荐

  • 主要目的是证明非奈利酮联合恩格列净治疗6个月在降低白蛋白尿方面优于任一单药治疗。
  • 纳入标准为2型糖尿病合并2-3期慢性肾脏病且尿白蛋白肌酐比值≥300至<5000 mg/g的成人。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitors (SGLT2is) can reduce both kidney and cardiovascular risks in people with CKD and T2D. Here we outline the design of a study to investigate whether dual therapy with finerenone and an SGLT2i is superior to either agent alone. METHODS: CONFIDENCE (NCT05254002) is a randomized, controlled, double-blind, double-dummy, international, multicenter, three-armed, parallel-group, 7.5 - to 8.5-month, Phase 2 study in 807 adults with T2D, stage 2-3 CKD and a urine albumin:creatinine ratio (UACR) ≥300-<5000 mg/g. The primary objective is to demonstrate that 6 months of dual therapy comprising finerenone and the SGLT2i empagliflozin is superior for reducing albuminuria versus either agent alone. Interventions will be once-daily finerenone 10 mg or 20 mg (target dose) plus empagliflozin 10 mg, or empagliflozin 10 mg alone, or finerenone 10 mg or 20 mg (target dose) alone. RESULTS: The primary outcome is a relative change from baseline in UACR among the three groups. Secondary outcomes will further characterize efficacy and safety, including changes in estimated glomerular filtration rate and incident hyperkalemia. CONCLUSIONS: CONFIDENCE is evaluating the safety, tolerability and efficacy of dual use of finerenone and an SGLT2i in adults with CKD and T2D. Should an additive effect be shown, early and efficient intervention with dual finerenone and SGLT2i therapy could slow disease progression and provide long-term benefits for people with CKD and T2D.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023. PMID: 35700142. doi:10.1093/ndt/gfac198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。